Intrauterine growth retardation (IUGR) is one of between the frontal lateral margin to the posthe most important fetal complications in perinatology. With the recent advances in ultrasonic measurements, the early recognition of fetal maldevelopment has become possible. In a prospective study of pregnancies with a fetal body weight ultrsonographically determined to be less than the 10th percentile of population, prenatal treatment consisting of daytime bedrest, high protein diet and oral administration of allylestrenol was assessed.
Intrauterine growth retardation (IUGR) is one of between the frontal lateral margin to the posthe most important fetal complications in perinatology. With the recent advances in ultrasonic measurements, the early recognition of fetal maldevelopment has become possible. In a prospective study of pregnancies with a fetal body weight ultrsonographically determined to be less than the 10th percentile of population, prenatal treatment consisting of daytime bedrest, high protein diet and oral administration of allylestrenol was assessed.
Material and Methods
A total of 30 pregnancies was investigated. In these pregnancies, the intrauterine gestational age was confirmed in the frist trimester of pregnancy by routine ultrasonic measurements of crown-rump length (CRL), using the standard of ROBINSON [5] . Both biparietal diameter (BPD) and abdominal circumference (AC) were measured in the third trimester. An ultrasonograph (^loka, SSD-256) with a 3.5 MHz transducer was used in both the first and third trimester measurements. The ultrasound tissue velocity used was 1,540 meters per second. CRL was measured with electronic calipers when the fetal echo complex was shown at its maximum length. BPD scan was obtained when the cranium became oval at an angle so that the clear midline structure and the lateral ventricles could be observed. The distance terior internal margin of the cranium was measured with electronic calipers. A photograph was made when the umbilical vein could be observed in a transverse scan at the right angle to the long axis of the fetus, and the AC was measured by a map reader (Uchida) (Fig. 1) . Then, the fetal weight was estimated from the BPD and AC measurements in accordance with the method of WARSOF et al. [14] and SHEPARD et al. [8] , using an equation of Iog 10 (body weight) = -1.599 + 0.144 (BPD) + 0.032 (AC) -0.111 (BPD 2 χ AC)/1,000 (equation I) and an equation of Iog 10 (body weight) = -1.7492 + 0.166 (BPD) + 0.046 (AC) -2.646 (AC χ BPD)/1,000 (equation II). In those 30 pregnancies, each the estimated fetal body weight was less than lOthpercentile of the intrauterine growth curve of NlSHlDA [4] for the Japanese at more than two ultrasonic measurements separated by two weeks. Maternal biochemical determinations were also performed on these pregnancies. The plasma unconjugated estriol value was measured with a CEA-IRE-Sorin RIA kit. Urinary estriol was determined on an 8-hour pooled specimen collected at night with a Teizo colorimetric kit and converted into that of a 24-hour urine. Plasma human placental lactogen (HPL) was assayed with a Kyorin EIA kit. Plasma unconjugated progesterone value was measured with a Daiichi RIA kit. Serum heat-stable alkaline phosphatase (HSAP) and leucine amino-peptidase (LAP) were determined colorimetrically. The patients were treated with daytime bedrest, high protein diet (2 g/kg/day) and oral administration of allylestrenol (GESTANON®, NIPPON ORGANON) in a dose of 30 mg/day until the time of delivery. Both ultrasonic and biochemical measurements were repeated weekly. For statistical analysis, Student's t-test was applied.
Results
The calculated values of the various measurements obtained prior to and following treatments were as follows.
Estimated fetal body weight
As shown in Tab. I, the initial gestational age of the 30 patients who were diagnosed as IUGR after at least two measurements taken two weeks apart were an average of 32.9 ± S.D. 2.4 weeks, and the estimated average fetal body weight was 1,362 ±316 g by equation I and 1,430 ±337 g by equation II. In the final assessment at 39.2 ± 1.8 weeks' gestation, the estimated average fetal body weight had increased to 2,678 ± 458 g by equation I and to 2,787 ± 477 g by equation II. Therefore, the average weekly gain of estimated fetal body weight was 223 ± 83 g by equation I and 219 ± 64 g by equation II, both of which were statistically significantly (p < 0.01) larger than the standard weekly increase at the 50th percentile level of NlSHlDA's intrauterine growth curve [4] , 171 ±42g, confirming the efficacy of prenatal threapy. Intrauterine weight chart of each case is illustrated on Fig. 2 [4] . The average placental weight of these cases was 490±95g. The fetal/placental weight ratio was 5.52 ± 0.64 on average, which was somewhat lower than that of normal pregnancy (usually, between 5.9 and 6.3). Fetal distress was not encountered in any of these cases during the course of delivery. All neonates had a one-minute APGAR Score of more than 8.
BPD and AC measurements
The BPD and AC measurements taken at 32.9 ± 2.4 weeks' gestation were 76 ± 6 mm and 25 ± 2 cm, respectively, and those at 39.2 ±1.8 weeks' gestation were 87 ± 4 mm and 33 ± 2 cm, respectively. On the basis of SABBAGHA's standard [6] , the BPD was below 10th percentile in 23 cases (76.7%) at the initial measurement, and in 22 (73.3 %) at the final measurement. Similarly, on the basis of TAMURA'S standard [11] , the AC was below the 10th percentile in 30 (100%) at the initial measurement, and in 21 (70.0%) at the final measurement. The average weekly increase of BPD was 1.8 ± 0.6 mm, which was insignificant to the standard gain of 1.6 ±0.3 mm according to SABBAGHA'S values [6] at 50th percentile level. The average weekly increase of AC was 1.3 ± 0.4 cm, which was a statistically significant (p<0.01) increase over the standard gain of 1.1 ± 0.2 cm according to TAMURA's value [11] at 50th percentile level.
Maternal biochemical values
Tab. II demonstrates the maternal plasma üncon-jugated estriol, urinary estriol, plasma HPL, plasma unconjugated progesterone, serum HSAP and serum LAP concentration values at 32.9 ± 2.4 weeks' gestation and the values following three weeks of prenatal treatment. The initial plasma unconugated estriol value was 2.9 ± 2.2 ng/ml on average, and in 20 patients (66.7%) the value was abnormally low on the basis of TULCHINSKY's standard [12] . Three weeks after treatment it was 5.2±3.5ng/ml which was a statistically significant (p<0.01) increase, but 15 (50.0%) 14 still showed abnormally low values. Likewise, the urinary estriol value at the initial measurement was an average of 13.3 ± 6.5 mg/day, and 8 cases (26.7 %) had abnormally low values on the basis of BEISCHER's standard [2] . Three weeks after treatment it increased to 23.4 ± 10.2 mg/day which was a statistically significant (p<0.01) increase, but only two (6.7%) of the patients had abnormally low values. The plasma HPL value was an average of 4.8 ± 1.2 Mg/ml at the initial measurement, and on the basis of VARMA's standard [13] 6 (20.0%) showed an abnormally low value. Three weeks after treatment the average value was 5.9 ±1.6 Mg/ml, which was statistically significant (p < 0.01) increase in value, but 3 (10.0%) had an abnormally low value. Initially, the plasma unconjugated progesterone value was 98 ± 26 ng/ml, but after three weeks' treatment it increased to 121 ±35 ng/ml, which was statistically significant (p<0.01) increase. The serum HSAP and LAP were initially 9.2 ± 7.1 KAU and 395 ± 207 mU/ml, respectively, and after three weeks' therapy they increased to 12.7 ± 7.9 KAU and 461 ± 177mU/inl respectively. Both values increased after treatment, but the increase was insignificant in either case. On the basis of YAMAGUCHI's standard [16] , the serum HSAP value was abnormally low in 7 patients (23.3%) initially and in one patient (3.3 %) after treatment.
Discussion
In the diagnosis of IUGR, it is important to confirm the gestational age. Since the fetal growth during the first trimester follows a definite growth pattern, it would be better to ascertain the gestational age by routine ultrasonic measurements of either CRL during 6 to 15 weeks' gestation or BPD during 10 to 19 weeks' gestation. There are several ultrasonic methods to estimate the fetal body weight using BPD, AC, total inrauterine volume and so on. WARSOF et al. [14] reported that a logarithmic equation (equation I in this study) with use of both BPD and AC had an absolute mean error of 228 g or 8.0%. Later, SHEPARD et al. [8] stated that equation I and a new equation (equation II in this study) had standard deviations of 212 g and 219 g respectively, when the fetal body weight was less than 2,500 g. In this study, the standard deviations of equation I and II were 178 g and 259 g respectively, for birth weight predictions. Correlation coefficients were 0.94 for both equations confirming that these equations for calculation of the estimated fetal body weight is useful in in the prenatal diagnosis of IUGR.
Having taken these facts into consideration, we measured and corrected the gestational age of our IUGR patients in the first trimester, calculated the estimated fetal body weights from the BPD and AC measurements during the third trimester, and selected those patients whose estimated fetal body weights derived from at least two ultrasonic measurements separated by two weeks were less than the 10th percentile of the intrauterine growth curve of NlSHIDA [4] for the Japanese. In IUGR, there is fetal hypoplasiä, with a decrease in both numbers of somatic cells and total DNA amounts in the tissue; there is also fetal malnutrition, with a decrease in both volume of somatic cells and protein/DNA ratio in the tissue. With the former, prenatal treatment is difficult; therefore, the underlying etiologies should be identified using antenatal diagnostic measures such as ultrasonography. For nutritional disorders, daytime bedrest was indicated to enhance the placental bloodflow, and high protein diet was encouraged as well. Allylestrenol has been reported to increase urinary HCG, pregnandiol, HPL and estriol in pregnant women [7, 9, 10] , and it has been reported to have a placentotrophic, pregnancy-maintaining and weight-promoting activity in the fetus [7] . Allylestrenol does not have estrogenic, androgenic and anabolic effects as some of the gestagens [1, 3, 15] . Indeed, the administration of allylestrenol was followed by significant increases of estriol, HPL and progesterone in this study, although some of those increments would be attributed to the increase in gestational age. An attempt to promote fetal weight without consideration of the functional status of the placenta is detrimental for the fetus, since this eventually increases the fetal volume/oxygen supply ratio. However, following allylestrenol treatment, the fetal/placental weight ratio was considerably smaller than that of normal pregnancy. Other important matters in the prenatal management IUGR would be:
1. to properly evaluate the fetal wellbeing and the intrauterine environment, 2. to determine the exact time of delivery while preventing both intrauterine fetal death and iatrogenic prematurity, and 3. to provide an efficient perinatal care to the newborn infant.
Summary
Prenatal treatment consisting of daytime bedrest, high protein diet and oral administration of allylestrenol was assessed in a prospective study of 30 patients with IUGR infants whose ultrasonically estimated body weight was less than the 10th percentile. In these pregnancies, the gestational age was confirmed in the first trimester, and the fetal weight was estimated from the BPD and AC measurements in the third trimester (Fig. 1) . Following treatment, ultrasonic and biochemical determinations were performed. As results:
1. The estimated fetal weight of 1,362 g at 32.9 g gestational weeks increased to 2,678 g at 39.2 weeks on average. The average weekly weight gain was significantly higher than the standard, and 16 cases (53.3%) were more than 10th percentile at birth (Tab. I, Fig. 2 
